Ono Received Manufacturing and Marketing Approval in Japan for XCOPRI® Tablets for the Treatment of Patients with Partial-onset Seizures, With or Without Secondary Generalized Seizures

Ono Pharma Enters into a Drug Discovery Partnership with Aitia in Neurological Diseases — Leveraging Cutting-Edge Causal AI-Based Digital Twins —

OPDIVO® Intravenous Infusion Approved in Taiwan for the Treatment of Resectable Non-Small Cell Lung Cancer with Neoadjuvant OPDIVO in Combination with Chemotherapy Followed by Surgery and Adjuvant Single-Agent OPDIVO

Ono Continues to be Selected for ESG Investment Indexes Adopted by GPIF

Ono Pharma Enters into a Drug Discovery Partnership with Mediar Therapeutics to Create Novel Antibody Therapeutics for Fibro-inflammatory Diseases